

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **利君國際醫藥(控股)有限公司**

**Lijun International Pharmaceutical (Holding) Co., Ltd.**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

### **COMPLETION OF THE PLACING AND SALE OF EXISTING SHARES AND SUBSCRIPTION FOR NEW SHARES**

The Board is pleased to announce that placing of the Placing Shares and sale of the Sale Shares have both been completed on 22 April 2010 in accordance with terms and conditions of the Placing Agreement and the Share Sale Agreement respectively.

The Board is also pleased to announce that the Subscriptions have also been completed on 27 April 2010 in accordance with terms and conditions of the Subscription Agreements.

Reference is made to the announcement of the Company dated 14 April 2010 (the “**Announcement**”) in relation to the placing and the sale of existing Shares and subscription for new Shares. Terms used in this announcement have the same meanings as defined in the Announcement unless otherwise stated.

## **COMPLETION OF THE PLACING AND SALE OF EXISTING SHARES**

The Board is pleased to announce that the placing of the Placing Shares and sale of the Sale Shares have both been completed on 22 April 2010 in accordance with terms and conditions of the Placing Agreement and the Share Sale Agreement respectively. An aggregate of 205,000,000 Placing Shares have been successfully placed to not less than six Funds of Value Partners, who and whose ultimate beneficial owners are independent of and not connected with and are not acting in concert with the Company and its connected persons, at the Placing Price of HK\$1.9 per Placing Share. Sale of the Sale Shares has also been completed and 30,000,000 Sale Shares have also been transferred to Atlantis Investment, who and whose ultimate beneficial owners are independent of and not connected with and are not acting in concert with the Company and its connected person.

The Placing Shares represent approximately 9.67% of the existing issued share capital of the Company and approximately 8.82% of the issued share capital of the Company as enlarged by the VP Subscription while the number of Sale Shares represents approximately 1.42% of the existing issued share capital of the Company and approximately 1.4% of the issued share capital of the Company as enlarged by the AI Subscription.

## **COMPLETION OF THE SUBSCRIPTION**

The Board is also pleased to announce that the Subscriptions have been completed on 27 April 2010 in accordance with the terms and conditions of the Subscription Agreements. An aggregate of 235,000,000 Subscription Shares, representing approximately 9.98% of the issued share capital of the Company as enlarged by the Subscriptions, have been allotted and issued to China Pharmaceutical by the Company at the Subscription Price of HK\$1.9 per Subscription Share.

## SHAREHOLDING STRUCTURE

The shareholding structure of the Company immediately before and after the placing and the sale of the Shares and the Subscriptions are summarised as follows:

Shareholder	Immediately before completion of the Placing and the Sale and the Subscriptions		Immediately after completion of the Placing and the Sale but before the Subscriptions		Immediately after completion of the Placing and the Sale and the Subscriptions	
	<i>Number of</i>		<i>Number of</i>		<i>Number of</i>	
	<i>Shares</i>	<i>%</i>	<i>Shares</i>	<i>%</i>	<i>Shares</i>	<i>%</i>
China Pharmaceutical (and parties acting in concert)	571,500,000	26.96%	336,500,000	15.88%	571,500,000	24.27%
Funds	–	–	205,000,000	9.67%	205,000,000	8.71%
Atlantis Investment	121,000,000	5.71%	151,000,000	7.12%	151,000,000	6.41%
Other shareholders	1,427,404,488	67.33%	1,427,404,488	67.33%	1,427,404,488	60.61%
	<u>2,119,904,488</u>	<u>100.00%</u>	<u>2,119,904,488</u>	<u>100.00%</u>	<u>2,354,904,488</u>	<u>100.00%</u>

On behalf of the Board  
**Sze Wing Kin, Pierre**  
*Company Secretary*

Hong Kong, 27 April 2010

*As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Huang Chao, Ms. Sun Xinglai, Mr. Wang Xian Jun, Mr. Duan Wei, Ms. Zhang Guifu, Mr. Bao Leyuan and Ms. Gao Shuping as executive Directors, Mr. Liu Zhiyong as non-executive Director, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non- executive Directors.*